Zevra Therapeutics Performance degli utili passati
Criteri Il passato verificati 3/6
Zevra Therapeutics ha registrato una crescita degli utili a un tasso medio annuo di 29.2%, mentre il settore Pharmaceuticals ha registrato utili in crescita a un tasso medio annuo di 10.7%. I ricavi sono stati in crescita a un tasso medio annuo di 39.6%. Il ritorno sul capitale proprio di Zevra Therapeutics è 60.4% e ha margini netti di 95.7%.
Informazioni chiave
29.25%
Tasso di crescita degli utili
48.40%
Tasso di crescita dell'EPS
| Pharmaceuticals Crescita del settore | 5.95% |
| Tasso di crescita dei ricavi | 39.61% |
| Rendimento del capitale proprio | 60.36% |
| Margine netto | 95.68% |
| Ultimo aggiornamento sugli utili | 31 Mar 2026 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Aggiornamento della narrazione • Jul 02
ZVRA: Extended Patent Exclusivity May Support Longer NPC Revenue Runway
The analyst price target for Zevra Therapeutics has shifted from $18 to $21, with analysts pointing to extended Miplyffa patent exclusivity and updated cash flow assumptions as key drivers of their higher valuation work. Analyst Commentary on Zevra Therapeutics Recent Street research on Zevra Therapeutics has focused on how extended Miplyffa intellectual property coverage could affect long term cash flow modeling, with several firms updating their price targets and assumptions around the duration of exclusivity.
Aggiornamento della narrazione • Jun 18
ZVRA: Extended Rare Disease IP Runway Will Drive Future Upside Potential
Analysts have raised the fair value estimate for Zevra Therapeutics to $35 from $26, aligning it with updated Street price targets in the $27 to $35 range, as they incorporate extended Miplyffa intellectual property protection and a higher future P/E assumption into their models. Analyst Commentary Recent research updates on Zevra Therapeutics cluster around one theme: bullish analysts are reassessing the stock’s upside as they factor in longer intellectual property protection for Miplyffa and refine their cash flow models.
Nuova narrazione • Jun 09
Discounted Exit Multiple Approach (DEM)
Disclaimer: This financial analysis is for informational purposes only and does not constitute investment advice. Zevra Therapeutics is a rare disease pharmaceutical company fundamentally driven by a single commercial product.Aggiornamento della narrazione • Jun 03
ZVRA: NPC Diagnosis Expansion Will Drive Future Upside Potential
Analysts have raised their average price target for Zevra Therapeutics to $23 from $22, citing early Miplyffa adoption trends, positive views on potential expansion opportunities, and ongoing adjustments to growth, margin and P/E assumptions in their models. Analyst Commentary Bullish analysts are leaning into a constructive view on Zevra Therapeutics, framing the updated US$23 average price target as grounded in observable Miplyffa adoption trends and modeled upside from expansion opportunities.Aggiornamento della narrazione • Apr 23
ZVRA: NPC Diagnosis Expansion And EU Decision Will Drive Future Upside Potential
Narrative Update: Zevra Therapeutics The updated analyst price target for Zevra Therapeutics is now $23, a $1 increase, as analysts point to the launch progress of Miplyffa, expectations for continued U.S. market penetration, and potential future catalysts including EU approval, patent term extension, and celiprolol development in VEDS. Analyst Commentary Bullish analysts are highlighting Zevra Therapeutics as a name where current valuation is closely linked to the rollout of Miplyffa and a set of identifiable potential catalysts.Aggiornamento della narrazione • Apr 08
ZVRA: NPC Diagnosis Expansion Will Drive Future Upside Potential
Analysts have maintained Zevra Therapeutics' fair value estimate at $26.00, with slight tweaks to growth, margin, and future P/E assumptions. Recent Street research highlights a $23 price target, supported by views that current pricing reflects conservative Miplyffa adoption and potential upside from broader patient reach and future regulatory or pipeline milestones.Aggiornamento della narrazione • Mar 24
ZVRA: Expanding NPC Diagnosis And EU Decision Will Drive Future Upside
Analysts have kept Zevra Therapeutics' fair value estimate steady at $26.00 while updating their assumptions on Miplyffa's launch trajectory and potential upside from EU approval, expanded U.S. adoption, and celiprolol optionality, which they note is reflected in Street price targets moving toward $23.00. Analyst Commentary Bullish analysts are framing Zevra's current share price as tied closely to conservative expectations for Miplyffa, largely anchored to the already diagnosed U.S. Niemann Pick type C population.Seeking Alpha • Mar 10
Zevra Therapeutics: Miplyffa Uptake Validates Rare Disease Commercial Model
Summary Zevra Therapeutics delivered robust FY25 results, with 350% revenue growth to $106.5M and a GAAP EPS of $1.40, driven by Miplyffa’s commercial launch. Miplyffa’s rapid adoption in the ultra-rare NPC market, supported by expanded payer coverage and diagnostic initiatives, underpins ZVRA’s strong commercial momentum. ZVRA trades at discounted valuation multiples (16.9x forward P/E, 10.7x EV/EBIT), reflecting market caution over one-time income and earnings sustainability. Global expansion, especially pending EMA review and early international patient access, positions ZVRA for further upside beyond its U.S.-driven growth. Read the full article on Seeking AlphaAggiornamento della narrazione • Mar 10
ZVRA: Growing NPC Access And Data Will Support Long-Term Rare Disease Upside
Analysts have maintained their $26.00 price target for Zevra Therapeutics, citing updated assumptions that reflect slightly different estimates for revenue growth, profit margins, and future P/E, without materially changing their overall view of the stock's valuation. What's in the News Zevra Therapeutics appointed Justin Renz as Chief Financial Officer, effective March 9, 2026.Aggiornamento della narrazione • Feb 24
ZVRA: Expanded Access And NPC Data Will Support Long-Term Rare Disease Upside
Analysts have kept their Zevra Therapeutics price target steady at $26.00. This points to largely unchanged fair value assumptions, even as they refine inputs such as revenue growth, profit margins and future P/E expectations.Aggiornamento della narrazione • Feb 09
ZVRA: Expanded Access And NPC Data Will Support Long-Term Rare Disease Upside
Analysts have maintained their price target on Zevra Therapeutics at $26.00, citing only modest tweaks to assumptions around revenue growth, profit margins, the discount rate, and future P/E that did not materially change their overall view. What's in the News Zevra presented four posters at the 22nd Annual WORLDSymposium highlighting new data on MIPLYFFA (arimoclomol) for Niemann Pick Disease Type C.Aggiornamento della narrazione • Jan 26
ZVRA: Expanded Access Deal Will Support Long-Term Rare Disease Upside
Narrative Update: Zevra Therapeutics Analyst Price Target The analyst price target for Zevra Therapeutics is now set at US$26.00. Analysts cite small adjustments to revenue growth assumptions, profit margin expectations, and future P/E estimates as key drivers for the updated view.Aggiornamento della narrazione • Jan 11
ZVRA: Expanded Rare Disease Access Agreement Will Support Long-Term Upside
Analysts have maintained their price target for Zevra Therapeutics at US$26.00, citing only modest adjustments to assumptions around revenue growth, profit margins and future P/E. Taken together, these changes do not alter their overall view of the company’s valuation.Aggiornamento della narrazione • Dec 26
ZVRA: Future Rare Disease Portfolio Will Support Long-Term Upside
Analysts have modestly increased their price target on Zevra Therapeutics to $26.00 per share, citing slightly stronger long term revenue growth and profit margin assumptions, alongside a marginally lower projected future price to earnings multiple. What's in the News Chief Financial Officer and Treasurer R.Aggiornamento della narrazione • Dec 12
ZVRA: Future Rare Disease Approvals Will Drive Long-Term Upside
Analysts have reduced their price target on Zevra Therapeutics by 3.00 dollars to 26.00 dollars, citing expectations for slower revenue growth, slightly lower profit margins, and a modestly higher discount rate, partially offset by a lower anticipated future price to earnings multiple. What's in the News Chief Financial Officer and Treasurer R.Articolo di analisi • Nov 08
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates
It's been a mediocre week for Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) shareholders, with the stock dropping 13% to...Articolo di analisi • Nov 03
Zevra Therapeutics (NASDAQ:ZVRA) Is Using Debt Safely
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Articolo di analisi • Sep 08
What You Can Learn From Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) P/S After Its 26% Share Price Crash
Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) shares have had a horrible month, losing 26% after a relatively good period...Articolo di analisi • Jul 10
Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) 26% Jump Shows Its Popularity With Investors
Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) shares have continued their recent momentum with a 26% gain in the last month...Articolo di analisi • May 22
Revenues Tell The Story For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) As Its Stock Soars 26%
Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) shareholders would be excited to see that the share price has had a great...
Nuova narrazione • Apr 29
MIPLYFFA Launch Will Spark European Expansion In 2025
Successful MIPLYFFA launch and European expansion plans indicate potential revenue growth and stable streams through strong demand and patient engagement.Articolo di analisi • Mar 10
Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects
When close to half the companies in the Pharmaceuticals industry in the United States have price-to-sales ratios (or...Articolo di analisi • Nov 15
Here's What Analysts Are Forecasting For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Third-Quarter Results
As you might know, Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) last week released its latest third-quarter, and things did...Articolo di analisi • Aug 30
Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects As Shares Rocket 34%
Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) shares have continued their recent momentum with a 34% gain in the last month...Articolo di analisi • Jul 12
Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) 26% Jump Shows Its Popularity With Investors
Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) shareholders have had their patience rewarded with a 26% share price jump in...Ripartizione dei ricavi e delle spese
Ripartizione dei ricavi e delle spese
Come Zevra Therapeutics guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storico di utili e ricavi
| Data | Ricavi | Utili | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 31 Mar 26 | 122 | 117 | 79 | 14 |
| 31 Dec 25 | 106 | 78 | 78 | 13 |
| 30 Sep 25 | 84 | 30 | 73 | 18 |
| 30 Jun 25 | 62 | -3 | 73 | 26 |
| 31 Mar 25 | 41 | -92 | 65 | 33 |
| 31 Dec 24 | 24 | -106 | 55 | 42 |
| 30 Sep 24 | 24 | -90 | 54 | 44 |
| 30 Jun 24 | 24 | -67 | 44 | 46 |
| 31 Mar 24 | 28 | -49 | 38 | 43 |
| 31 Dec 23 | 27 | -46 | 35 | 39 |
| 30 Sep 23 | 17 | -20 | 25 | 34 |
| 30 Jun 23 | 17 | -17 | 23 | 27 |
| 31 Mar 23 | 9 | -38 | 20 | 25 |
| 31 Dec 22 | 10 | -27 | 16 | 19 |
| 30 Sep 22 | 11 | -35 | 13 | 16 |
| 30 Jun 22 | 10 | -30 | 11 | 12 |
| 31 Mar 22 | 20 | -17 | 10 | 10 |
| 31 Dec 21 | 29 | -63 | 9 | 10 |
| 30 Sep 21 | 28 | -65 | 9 | 10 |
| 30 Jun 21 | 28 | -66 | 9 | 9 |
| 31 Mar 21 | 23 | -55 | 8 | 8 |
| 31 Dec 20 | 13 | -13 | 8 | 8 |
| 30 Sep 20 | 12 | -14 | 7 | 8 |
| 30 Jun 20 | 22 | -8 | 10 | 10 |
| 31 Mar 20 | 15 | -18 | 11 | 12 |
| 31 Dec 19 | 13 | -25 | 11 | 19 |
| 30 Sep 19 | 11 | -24 | 13 | 23 |
| 30 Jun 19 | 0 | -42 | 12 | 32 |
| 31 Mar 19 | 0 | -43 | 13 | 38 |
| 31 Dec 18 | 0 | -56 | 13 | 41 |
| 30 Sep 18 | 0 | -62 | 13 | 41 |
| 30 Jun 18 | 0 | -57 | 13 | 33 |
| 31 Mar 18 | 0 | -53 | 13 | 28 |
| 31 Dec 17 | 0 | -43 | 13 | 20 |
| 30 Sep 17 | 0 | -43 | 13 | 23 |
| 30 Jun 17 | 0 | -45 | 13 | 21 |
| 31 Mar 17 | 0 | -30 | 14 | 21 |
| 31 Dec 16 | 0 | -17 | 14 | 20 |
| 30 Sep 16 | 0 | -16 | 14 | 17 |
| 30 Jun 16 | 0 | -13 | 13 | 17 |
| 31 Mar 16 | 0 | -52 | 12 | 15 |
| 31 Dec 15 | 0 | -55 | 9 | 14 |
Guadagni di qualità: ZVRA ha un livello elevato di guadagni non monetari.
Margine di profitto in crescita: ZVRA è diventata redditizia in passato.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: ZVRA è diventata redditizia negli ultimi 5 anni, aumentando i guadagni del 29.2% all'anno.
Accelerare la crescita: ZVRA è diventata redditizia nell'ultimo anno, rendendo difficile confrontare il tasso di crescita degli utili con la media quinquennale.
Guadagni vs Settore: ZVRA è diventata redditizia nell'ultimo anno, rendendo difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Pharmaceuticals ( -4.8% ).
Rendimento del capitale proprio
ROE elevato: Il Return on Equity ( 60.4% ) di ZVRA è considerato eccezionale.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/12 14:31 |
| Prezzo dell'azione a fine giornata | 2026/07/10 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Zevra Therapeutics, Inc. è coperta da 17 analisti. 9 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Kenneth Trbovich | Brean Capital Historical (Janney Montgomery) |
| Kambiz Yazdi | BTIG |
| Sumant Satchidanand Kulkarni | Canaccord Genuity |